
  
    
      
        Background_NNP
        Jet_NNP injection_NN is_VBZ a_DT relatively_RB simple_JJ and_CC low-cost_JJ method_NN
        for_IN gene_NN transfer_NN into_IN somatic_JJ tissues_NNS [_NN 1_CD ]_NN ._. Aside_RB from_IN
        the_DT injector_NN ,_, no_DT special_JJ equipment_NN or_CC solutions_NNS are_VBP
        required_VBN ._. Plasmid_NNP DNA_NNP is_VBZ suspended_VBN at_IN the_DT desired_VBN
        concentration_NN in_IN one_CD of_IN several_JJ types_NNS of_IN solution_NN and_CC
        injected_VBN into_IN tissue_NN ._. More_JJR than_IN one_CD plasmid_NN construct_VB can_MD
        be_VB injected_VBN simultaneously_RB ._. Injection_NNP of_IN antigen_NN encoding_VBG
        plasmids_NNS can_MD be_VB combined_VBN with_IN either_DT adjuvants_NNS or_CC plasmids_NNS
        encoding_VBG immune_JJ enhancing_VBG cytokines_NNS ._. Low-volume_NNP jet_NN
        injection_NN deliberately_RB limits_VBZ the_DT volume_NN of_IN the_DT injected_VBN
        solution_NN and_CC is_VBZ utilized_JJ to_TO target_VB delivery_NN to_TO small_JJ tissue_NN
        areas_NNS [_NN 2_CD ]_NN ._.
        In_IN mice_NNS ,_, multiple_JJ different_JJ routes_NNS of_IN DNA_NNP immunization_NN
        have_VBP been_VBN used_VBN successfully_RB [_NN 3_CD ]_NN ._. Particle_NNP bombardment_NN of_IN
        skin_NN is_VBZ reported_VBN to_TO be_VB superior_JJ to_TO both_DT intra-dermal_JJ and_CC
        intra-muscular_JJ needle_NN and_CC syringe_NN injection_NN for_IN induction_NN
        of_IN immunity_NN in_IN mice_NNS when_WRB compared_VBN directly_RB [_NN 4_CD 5_CD 6_CD 7_CD 8_CD ]_NN ._.
        In_IN Aotus_NNP monkeys_NNS and_CC pigs_NNS ,_, intra-dermal_JJ administration_NN of_IN
        DNA_NNP vaccine_NN by_IN needle_NN and_CC syringe_NN is_VBZ reported_VBN to_TO be_VB more_RBR
        effective_JJ at_IN inducing_VBG an_DT immune_JJ response_NN than_IN
        intra-muscular_JJ administration_NN by_IN needle_NN and_CC syringe_NN [_NN 9_CD 10_CD
        ]_NN ._. High-volume_NNP jet_NN injection_NN (_( 500_CD μl_NN )_) of_IN either_DT 100_CD or_CC
        1000_CD μg_NN DNA_NNP into_IN ovine_NN muscle_NN or_CC mammary_JJ gland_NN [_NN 11_CD 12_CD ]_NN or_CC
        500_CD μg_NN DNA_NNP into_IN four_CD separate_JJ muscle_NN sites_NNS in_IN rabbits_NNS [_NN 13_CD
        ]_NN induces_VBZ humoral_NN immunity_NN ._.
        Multiple_NNP studies_NNS have_VBP demonstrated_VBN that_DT particle_NN
        bombardment_NN of_IN skin_NN elicits_NNS immune_JJ responses_NNS in_IN larger_JJR
        animals_NNS [_NN 14_CD 15_CD 16_CD 17_CD 18_CD ]_NN ._. Similarly_RB ,_, high-volume_JJ jet_NN
        injection_NN (_( 100_CD μl_NN )_) of_IN either_DT 50_CD or_CC 250_CD μg_NN DNA_NNP into_IN the_DT skin_NN
        of_IN primates_NNS induces_VBZ immunity_NN [_NN 19_CD ]_NN ._. Delivery_NN to_TO the_DT oral_JJ
        mucosa_NN by_IN jet_NN injection_NN elicited_JJ a_DT higher_JJR IgA_NNP response_NN than_IN
        intranasal_NN delivery_NN in_IN mice_NNS [_NN 20_CD ]_NN ._. However_RB ,_, none_NN of_IN these_DT
        studies_NNS compared_VBD different_JJ intracutaneous_JJ DNA_NNP delivery_NN
        methods_NNS within_IN the_DT same_JJ study_NN ._.
        This_DT investigation_NN tested_VBD the_DT ability_NN of_IN low-volume_JJ jet_NN
        injection_NN to_TO target_VB delivery_NN of_IN a_DT DNA_NNP vaccine_NN to_TO the_DT skin_NN
        for_IN the_DT purpose_NN of_IN inducing_VBG immunity_NN ._. A_DT direct_JJ comparison_NN
        of_IN the_DT new_JJ methodology_NN to_TO the_DT established_VBN techniques_NNS of_IN
        particle_NN bombardment_NN and_CC needle_NN and_CC syringe_NN injection_NN was_VBD
        performed_VBN ._. The_DT experiments_NNS demonstrated_VBN that_IN low-volume_JJ jet_NN
        injection_NN successfully_RB induced_VBD immunity_NN in_IN rabbits_NNS ._.
        Moreover_RB ,_, there_EX were_VBD no_DT significant_JJ differences_NNS between_IN jet_NN
        injection_NN and_CC particle_NN bombardment_NN in_IN the_DT maximal_NN antibody_NN
        titers_NNS or_CC number_NN of_IN injections_NNS before_IN response_NN ._. In_IN contrast_NN
        no_DT rabbits_NNS receiving_VBG DNA_NNP vaccine_NN by_IN needle_NN and_CC syringe_NN
        injection_NN developed_VBD an_DT antibody_NN response_NN ._. In_IN the_DT low-volume_JJ
        jet_NN injection_NN and_CC particle_NN bombardment_NN groups_NNS ,_, gene_NN
        expression_NN levels_NNS in_IN the_DT skin_NN did_VBD not_RB predict_VB the_DT magnitude_NN
        of_IN the_DT immune_JJ response_NN ._. While_IN immune_JJ responses_NNS were_VBD
        comparable_JJ ,_, luciferase_NN gene_NN expression_NN levels_NNS in_IN the_DT skin_NN
        following_VBG particle_NN bombardment_NN were_VBD 10_CD -_: 100_CD times_NNS higher_JJR
        than_IN low-volume_JJ jet_NN injection_NN ._.
      
      
        Results_NNS and_CC discussion_NN
        
          Low-volume_NNP jet_NN injection_NN targets_NNS delivery_NN of_IN a_DT
          plasmid_NN DNA_NNP solution_NN to_TO the_DT epidermis_NNS and_CC dermis_NNS of_IN
          rabbits_NNS
          Injection_NNP path_NN lengths_NNS were_VBD measured_VBN following_VBG
          low-volume_JJ jet_NN injection_NN of_IN a_DT 1_CD %_NN India_NNP ink_NN solution_NN ._.
          Injection_NNP paths_NNS averaged_VBD between_IN 0_CD ._. 5_CD mm_NN and_CC 0_CD ._. 75_CD mm_NN
          (_( Figure_NN 1_LS )_) ._. The_DT injection_NN paths_NNS did_VBD not_RB extend_VB through_IN
          the_DT dermis_NNS ._. These_DT experiments_NNS show_VBP that_IN low-volume_JJ jet_NN
          injection_NN specifically_RB targeted_VBD delivery_NN of_IN a_DT DNA_NNP
          solution_NN to_TO the_DT skin_NN and_CC that_IN the_DT injection_NN paths_NNS did_VBD not_RB
          reach_VB into_IN the_DT underlying_VBG tissue_NN ._.
        
        
          Optimal_NNP injection_NN parameters_NNS for_IN low-volume_JJ jet_NN
          injection_NN ,_, particle_NN bombardment_NN and_CC needle_NN and_CC syringe_NN
          injection_NN
          Optimal_NNP injection_NN parameters_NNS for_IN each_DT technique_NN were_VBD
          established_VBN by_IN comparing_VBG relative_JJ mean_NN expression_NN levels_NNS
          of_IN the_DT luciferase_NN reporter_NN gene_NN in_IN the_DT skin_NN 48_CD hours_NNS
          after_IN injection_NN ._. Injection_NNP parameters_NNS that_WDT yielded_VBD the_DT
          highest_JJS levels_NNS of_IN luciferase_NN expression_NN were_VBD selected_VBN as_IN
          optimal_NN ._. Particle_NNP bombardment_NN produced_VBD the_DT highest_JJS mean_NN
          levels_NNS of_IN luciferase_NN activity_NN (_( Table_NNP 1_LS )_) ._. Mean_VB luciferase_NN
          activity_NN following_VBG low-volume_JJ jet_NN injection_NN was_VBD 10_CD -_: 100_CD
          fold_VB lower_JJR than_IN following_VBG particle_NN bombardment_NN ._. Mean_VB
          luciferase_NN activity_NN following_VBG needle_NN and_CC syringe_NN
          injection_NN was_VBD 50_CD fold_VB lower_JJR than_IN jet_NN injection_NN ._.
        
        
          Maximal_NNP antibody_NN titers_NNS and_CC number_NN of_IN injections_NNS
          before_IN response_NN following_VBG low-volume_JJ jet_NN injection_NN ,_,
          particle_NN bombardment_NN ,_, and_CC needle_NN and_CC syringe_NN delivery_NN of_IN
          a_DT DNA_NNP vaccine_NN to_TO the_DT skin_NN
          Injections_NNP of_IN plasmid_NN DNA_NNP encoding_VBG the_DT Hepatitis_NNP B_NNP
          Surface_NNP Antigen_NNP (_( HBSAg_NNP )_) were_VBD performed_VBN at_IN Days_NNS 0_CD ,_, 14_CD and_CC
          28_CD ._. Antibody_NNP titers_NNS were_VBD determined_VBN prior_RB to_TO any_DT
          injection_NN (_( Day_NNP 0_CD )_) ,_, two_CD weeks_NNS after_IN each_DT of_IN the_DT three_CD
          injections_NNS (_( Days_NNS 14_CD ,_, 28_CD ,_, and_CC 42_CD )_) ,_, and_CC four_CD weeks_NNS after_IN
          the_DT third_JJ and_CC final_JJ injection_NN (_( Day_NNP 56_CD )_) ._. By_IN days_NNS 14_CD and_CC 28_CD
          two_CD of_IN five_CD rabbits_NNS immunized_JJ by_IN low-volume_JJ jet_NN injection_NN
          demonstrated_VBD a_DT statistically_RB significant_JJ and_CC titratable_JJ
          response_NN at_IN serial_NN time_NN points_NNS that_WDT persisted_VBD through_IN day_NN
          56_CD (_( Figure_NN 2_CD A_DT )_) (_( ANOVA_NNP ,_, 
          P_NN =_SYM 0_CD ._. 009_CD at_IN the_DT 1_CD :_: 250_CD dilution_NN ;_: 
          P_NN =_SYM 0_CD ._. 003_CD at_IN the_DT 1_CD :_: 2_CD ,_, 500_CD dilution_NN
          at_IN day_NN 56_CD )_) ._. The_DT number_NN of_IN injections_NNS before_IN response_NN and_CC
          the_DT maximal_NN antibody_NN responses_NNS were_VBD comparable_JJ to_TO rabbits_NNS
          that_WDT received_VBD DNA_NNP immunization_NN by_IN particle_NN bombardment_NN ._.
          By_IN days_NNS 14_CD (_( 1_LS )_) and_CC 42_CD (_( 2_LS )_) three_CD of_IN five_CD rabbits_NNS immunized_JJ
          by_IN particle_NN bombardment_NN demonstrated_VBD a_DT statistically_RB
          significant_JJ response_NN at_IN serial_NN time_NN points_NNS (_( Figure_NN 2_CD B_NNP )_) ._.
          One_CD rabbit_NN expired_VBD during_IN anesthesia_NN at_IN the_DT day_NN
          28_CD -_: injection_NN time_NN point_NN ._. At_IN day_NN 56_CD the_DT immune_JJ response_NN
          was_VBD statistically_RB significant_JJ only_RB at_IN the_DT 1_CD :_: 250_CD dilution_NN
          in_IN the_DT two_CD remaining_VBG rabbits_NNS (_( ANOVA_NNP ,_, 
          P_NN <_NN 0_CD ._. 001_CD at_IN the_DT 1_CD :_: 250_CD dilution_NN ;_:
          
          P_NN =_SYM 0_CD ._. 609_CD at_IN the_DT 1_CD :_: 2_CD ,_, 500_CD dilution_NN )_) ._.
          There_EX was_VBD no_DT statistically_RB significant_JJ difference_NN in_IN
          maximal_NN antibody_NN titers_NNS between_IN low-volume_JJ jet_NN injection_NN
          and_CC particle_NN bombardment_NN (_( ANOVA_NNP ,_, 
          P_NN =_SYM 0_CD ._. 875_CD )_) (_( Figure_NN 3_LS )_) ._. In_IN contrast_NN
          to_TO immunization_NN with_IN either_DT low-volume_JJ jet_NN or_CC particle_NN
          bombardment_NN ,_, there_EX was_VBD no_DT significant_JJ titratable_JJ antibody_NN
          response_NN in_IN rabbits_NNS that_WDT received_VBD DNA_NNP immunization_NN by_IN
          needle_NN and_CC syringe_NN injection_NN (_( ANOVA_NNP ,_, 
          P_NN =_SYM 0_CD ._. 062_CD at_IN the_DT 1_CD :_: 250_CD dilution_NN ;_: 
          P_NN =_SYM 0_CD ._. 140_CD at_IN the_DT 1_CD :_: 2_CD ,_, 500_CD dilution_NN
          at_IN day_NN 56_CD )_) ._. Longer-term_NNP experiments_NNS and_CC larger_JJR groups_NNS of_IN
          rabbits_NNS will_MD be_VB required_VBN to_TO determine_VB if_IN persistence_NN of_IN
          antibody_NN is_VBZ different_JJ between_IN the_DT low-volume_JJ jet_NN injected_VBN
          and_CC particle_NN bombardment_NN groups_NNS ._.
          The_DT experiments_NNS demonstrate_VBP that_DT intradermal_NN
          low-volume_JJ jet_NN injection_NN of_IN a_DT DNA_NNP vaccine_NN can_MD be_VB utilized_JJ
          to_TO elicit_NN immune_JJ responses_NNS ._. The_DT low-volume_JJ jet_NN injection_NN
          method_NN was_VBD comparable_JJ to_TO the_DT more_RBR established_JJ technique_NN
          of_IN particle_NN bombardment_NN and_CC was_VBD significantly_RB better_JJR than_IN
          the_DT established_VBN technique_NN of_IN needle_NN and_CC syringe_NN
          injection_NN ._.
        
      
      
        Conclusion_NNP
        Low-volume_NNP jet_NN injection_NN is_VBZ an_DT effective_JJ new_JJ methodology_NN
        for_IN intradermal_NN DNA_NNP immunization_NN that_WDT has_VBZ advantages_NNS over_IN
        the_DT established_VBN techniques_NNS of_IN needle_NN and_CC syringe_NN injection_NN
        and_CC particle_NN bombardment_NN ._. It_PRP is_VBZ more_RBR effective_JJ than_IN needle_NN
        and_CC syringe_NN injection_NN and_CC is_VBZ simpler_JJR to_TO perform_VB than_IN
        particle_NN bombardment_NN because_IN the_DT plasmid_NN DNA_NNP solution_NN can_MD
        be_VB injected_VBN directly_RB rather_RB than_IN being_VBG precipitated_VBD onto_IN
        specific_JJ particles_NNS ._. High_JJ levels_NNS of_IN gene_NN expression_NN were_VBD not_RB
        required_VBN for_IN successful_JJ intradermal_NN genetic_JJ immunization_NN by_IN
        low-volume_JJ jet_NN injection_NN ._. Gene_NNP expression_NN levels_NNS following_VBG
        particle_NN bombardment_NN were_VBD 10_CD -_: 100_CD fold_VB higher_JJR than_IN those_DT
        found_VBN following_VBG low-volume_JJ jet_NN injection_NN but_CC the_DT immune_JJ
        response_NN was_VBD equivalent_NN ._. The_DT disassociation_NN between_IN local_JJ
        gene_NN expression_NN levels_NNS in_IN the_DT injected_VBN skin_NN and_CC immune_JJ
        response_NN is_VBZ consistent_JJ with_IN a_DT previous_JJ report_NN [_NN 16_CD ]_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Plasmids_NNP
          A_DT plasmid_NN encoding_VBG the_DT HBSAg_NNP under_IN the_DT control_NN of_IN the_DT
          Human_NNP Cytomegalovirus_NNP Immediate_NNP Early_RB gene_NN I_PRP (_( HCMVIE_NNP 1_LS )_)
          enhancer_NN /_NN promoter_NN (_( pRc_NN /_NN CMV-HBs_NNP (_( S_NNP )_) was_VBD obtained_VBN from_IN
          Aldevron_NNP (_( Fargo_NNP ,_, ND_NNP )_) [_NN 20_CD ]_NN ._. A_DT plasmid_NN encoding_VBG the_DT
          firefly_RB luciferase_NN gene_NN under_IN the_DT control_NN of_IN the_DT HCMVIE_NNP 1_CD
          enhancer_NN /_NN promoter_NN (_( pHCMVIE_NN 1_CD -_: luciferase_NN )_) was_VBD used_VBN to_TO
          measure_VB relative_JJ gene_NN expression_NN levels_NNS following_VBG gene_NN
          transfer_NN by_IN low-volume_JJ jet_NN injection_NN ,_, particle_NN
          bombardment_NN and_CC needle_NN and_CC syringe_NN injection_NN [_NN 2_CD ]_NN ._.
          Plasmids_NNP were_VBD propagated_JJ in_IN DH_NNP 5_CD α_NN cells_NNS and_CC purified_JJ by_IN
          Bio_NNP 101_CD Merlin_NNP Core_NNP Services_NNPS (_( Carlsbad_NNP ,_, CA_NNP )_) ._.
        
        
          Animals_NNS ,_, skin_NN preparation_NN ,_, and_CC injection_NN
          schedules_NNS
          Twenty-five_CD male_JJ New_NNP Zealand_NNP White_NNP rabbits_NNS were_VBD
          obtained_VBN at_IN 2_CD -_: 3_CD kg_NN in_IN weight_NN ._. Animals_NNS were_VBD purchased_VBN from_IN
          a_DT commercial_JJ vendor_NN (_( Covance_NNP ,_, Denver_NNP ,_, PA_NNP )_) ._. Health_NN status_NN
          was_VBD evaluated_VBN quarterly_JJ by_IN the_DT vendor_NN and_CC the_DT animals_NNS
          were_VBD free_JJ of_IN tested_VBN pathogens_NNS (_( other_JJ than_IN 
          Bordetella_NN bronchiseptica_NN and_CC
          rotavirus_JJ but_CC these_DT were_VBD not_RB expected_VBN to_TO interfere_VB with_IN
          the_DT current_JJ study_NN )_) ._. The_DT rabbits_NNS were_VBD in_IN excellent_JJ health_NN
          and_CC not_RB symptomatic_JJ ._. The_DT rabbits_NNS were_VBD anesthetized_JJ with_IN
          40_CD mg_NN /_NN kg_NN Ketamine_NNP (_( 100_CD mg_NN /_NN ml_NN ,_, )_) and_CC 3_CD mg_NN /_NN kg_NN Xylazine_NNP (_( 20_CD
          mg_NN /_NN ml_NN )_) prior_RB to_TO each_DT injection_NN ._. In_IN preparation_NN for_IN
          injection_NN ,_, the_DT dorsal_NN skin_NN was_VBD shaved_VBN ,_, treated_VBN with_IN a_DT
          depilatory_NN ,_, and_CC washed_VBD with_IN a_DT chlorhexidine_NN scrub_NN
          followed_VBN by_IN 70_CD %_NN alcohol_NN ._. Following_VBG injections_NNS 0_CD ._. 05_CD mg_NN /_NN kg_NN
          Buprenorphine_NNP (_( 0_CD ._. 3_LS mg_NN /_NN ml_NN )_) was_VBD given_VBN for_IN analgesia_NN ._.
          To_TO establish_VB skin_NN penetration_NN depth_NN following_VBG
          low-volume_JJ jet_NN injection_NN ,_, one_CD rabbit_NN was_VBD injected_VBN at_IN 6_CD
          different_JJ sites_NNS with_IN a_DT 1_CD %_NN India_NNP ink_NN solution_NN ._. The_DT skin_NN
          was_VBD removed_VBN at_IN necropsy_NN and_CC examined_VBD under_IN a_DT dissecting_VBG
          microscope_NN to_TO measure_VB the_DT length_NN of_IN the_DT injection_NN paths_NNS ._.
          To_TO establish_VB optimal_NN injection_NN conditions_NNS for_IN low-volume_JJ
          jet_NN injection_NN ,_, two_CD rabbits_NNS were_VBD injected_VBN at_IN a_DT total_NN of_IN 15_CD
          sites_NNS per_IN rabbit_NN with_IN pHCMVIE_NN 1_CD -_: luciferase_NN and_CC euthanized_JJ
          48_CD h_NN later_RB ._. The_DT injected_VBN skin_NN was_VBD removed_VBN at_IN necropsy_NN and_CC
          tested_VBN for_IN luciferase_NN activity_NN ._. When_WRB using_VBG particle_NN
          bombardment_NN the_DT goal_NN is_VBZ to_TO deliver_VB the_DT majority_NN of_IN gold_JJ
          particles_NNS into_IN the_DT epithelial_NN cell_NN layer_NN rather_RB than_IN the_DT
          deeper_JJR ,_, less_RBR cellular_JJ dermis_NNS [_NN 21_CD ]_NN ._. To_TO establish_VB skin_NN
          penetration_NN depth_NN following_VBG particle_NN bombardment_NN ,_, four_CD
          rabbits_NNS were_VBD injected_VBN at_IN eight_CD sites_NNS on_IN each_DT rabbit_NN ._. The_DT
          skin_NN was_VBD removed_VBN at_IN necropsy_NN and_CC fixed_VBN in_IN 10_CD %_NN neutral_JJ
          formalin_NN ,_, embedded_VBN by_IN standard_JJ methods_NNS ,_, and_CC 5_CD -_: micron_NN
          sections_NNS were_VBD prepared_VBN ._. Hematoxylin_NNP and_CC eosin_NN stained_JJ
          sections_NNS were_VBD examined_VBN under_IN the_DT microscope_NN to_TO determine_VB
          the_DT penetration_NN depth_NN ._. Gold_NN particles_NNS were_VBD found_VBN
          distributed_VBN primarily_RB in_IN the_DT epidermis_NNS and_CC minimally_RB in_IN
          the_DT superficial_JJ dermis_NNS of_IN the_DT rabbit_NN skin_NN (_( data_NNS not_RB
          shown_VBN )_) ._. To_TO establish_VB optimal_NN injection_NN conditions_NNS for_IN
          particle_NN bombardment_NN ,_, six_CD rabbits_NNS were_VBD injected_VBN at_IN a_DT
          total_NN of_IN 12_CD sites_NNS per_IN rabbit_NN with_IN pHCMVIE_NN 1_CD -_: luciferase_NN and_CC
          euthanized_JJ 48_CD h_NN later_RB ._. The_DT injected_VBN skin_NN was_VBD removed_VBN at_IN
          necropsy_NN and_CC tested_VBN for_IN luciferase_NN activity_NN ._. To_TO establish_VB
          optimal_NN conditions_NNS for_IN intra-dermal_JJ needle_NN and_CC syringe_NN
          injection_NN ,_, two_CD rabbits_NNS were_VBD injected_VBN at_IN a_DT total_NN of_IN 7_CD
          sites_NNS per_IN rabbit_NN with_IN pHCMVIE_NN 1_CD -_: luciferase_NN and_CC euthanized_JJ
          48_CD h_NN later_RB ._. The_DT injected_VBN skin_NN was_VBD removed_VBN at_IN necropsy_NN and_CC
          tested_VBN for_IN luciferase_NN activity_NN ._.
          For_IN the_DT immunization_NN experiments_NNS ,_, rabbits_NNS were_VBD
          injected_VBN at_IN three_CD time_NN points_NNS at_IN two_CD weeks_NNS intervals_NNS :_: 0_CD
          days_NNS ,_, 14_CD days_NNS and_CC 28_CD days_NNS ._. Three_CD ml_NN blood_NN was_VBD obtained_VBN
          from_IN an_DT ear_NN vein_NN prior_RB to_TO each_DT injection_NN and_CC two_CD weeks_NNS
          and_CC four_CD weeks_NNS following_VBG the_DT third_JJ and_CC final_JJ injection_NN ._.
          One_CD of_IN the_DT five_CD rabbits_NNS that_WDT received_JJ particle_NN
          bombardment_NN injection_NN died_VBD under_IN anesthesia_NN prior_RB to_TO the_DT
          second_JJ injection_NN ._. A_DT necropsy_NN was_VBD performed_VBN ,_, no_DT
          abnormalities_NNS were_VBD found_VBN ,_, and_CC the_DT death_NN was_VBD attributed_VBN to_TO
          anesthesia_NN ._.
        
        
          Optimization_NNP of_IN low-volume_JJ jet_NN injection_NN ,_, particle_NN
          bombardment_NN and_CC needle_NN and_CC syringe_NN injection_NN
          conditions_NNS
          Low-volume_NNP jet_NN injection_NN was_VBD performed_VBN with_IN a_DT
          prototype_NN low-volume_JJ jet_NN injector_NN with_IN adjustable_JJ
          injection_NN volume_NN and_CC pressure_NN ._. The_DT plasmid_NN DNA_NNP solution_NN
          at_IN 1_CD μg_NN /_NN μl_NN was_VBD prepared_VBN in_IN phosphate_NN buffered_JJ saline_NN
          (_( PBS_NNP )_) ._. The_DT injector_NN is_VBZ manufactured_VBN with_IN a_DT refillable_JJ
          liquid_JJ reservoir_NN that_WDT holds_VBZ 180_CD μl_NN and_CC can_MD rapidly_RB
          deliver_VB multiple_JJ injections_NNS to_TO the_DT same_JJ site_NN (_( EMS_NNP ,_,
          Konstanz_NNP ,_, Germany_NNP )_) [_NN 2_CD 22_CD ]_NN ._. For_IN optimization_NN of_IN the_DT jet_NN
          injection_NN experiments_NNS ,_, three_CD different_JJ injection_NN volume_NN
          settings_NNS (_( 5_CD -_: μl_NN ,_, 6_CD -_: μl_NN and_CC 7_CD -_: μl_NN )_) at_IN three_CD different_JJ
          pressures_NNS (_( 1_CD ,_, 2_CD and_CC 3_CD -_: Bar_NNP )_) were_VBD tested_VBN ._. When_WRB using_VBG
          low-volume_JJ jet_NN injection_NN for_IN intradermal_NN delivery_NN the_DT
          goal_NN is_VBZ contain_VB the_DT delivery_NN solution_NN within_IN the_DT
          epidermis_NNS and_CC dermis_NNS but_CC optimize_NN gene_NN expression_NN levels_NNS ._.
          Conditions_NNP for_IN optimal_NN gene_NN expression_NN were_VBD established_VBN
          by_IN testing_VBG luciferase_NN activity_NN in_IN the_DT skin_NN 48_CD h_NN following_VBG
          injection_NN of_IN pHCMVIE_NN 1_CD -_: luciferase_NN ._. Four_CD rapid_JJ injections_NNS
          at_IN each_DT volume_NN were_VBD used_VBN for_IN total_JJ DNA_NNP delivery_NN of_IN 20_CD μl_NN
          /_NN 20_CD μg_NN plasmid_NN DNA_NNP ,_, 24_CD μl_NN /_NN 24_CD μg_NN plasmid_NN DNA_NNP ,_, and_CC 28_CD μl_NN /_NN 28_CD
          μg_NN plasmid_NN DNA_NNP ._. The_DT injected_VBN fluid_NN remained_VBD within_IN the_DT
          dermis_NNS under_IN all_DT conditions_NNS ._. The_DT delivery_NN volume_NN with_IN the_DT
          highest_JJS mean_NN luciferase_NN expression_NN was_VBD chosen_VBN as_IN the_DT
          optimal_NN delivery_NN condition_NN for_IN the_DT immunization_NN studies_NNS ._.
          This_DT optimal_NN setting_VBG of_IN 28_CD μl_NN /_NN 28_CD μg_NN plasmid_NN DNA_NNP delivered_VBD
          at_IN 3_CD -_: Bar_NNP was_VBD utilized_JJ for_IN each_DT immunization_NN time_NN
          point_NN ._.
          A_DT Helios_NNP Gene_NNP Gun_NNP System_NNP ,_, (_( Bio-_NNP Rad_NNP Laboratories_NNPS ,_,
          Hercules_NNP ,_, CA_NNP )_) was_VBD utilized_JJ for_IN particle_NN bombardment_NN ._.
          Plasmid_NNP DNA_NNP was_VBD precipitated_VBD onto_IN gold_JJ particles_NNS 1_CD ._. 6_CD
          microns_NNS in_IN diameter_NN following_VBG standard_JJ protocols_NNS [_NN 21_CD ]_NN ._.
          Optimization_NNP conditions_NNS tested_VBN included_VBD the_DT helium_NN
          pressure_NN ,_, concentration_NN of_IN polyvinylpyrrolidone_NN (_( PVP_NNP )_) ,_,
          amount_NN of_IN carrier_NN gold_NN and_CC DNA_NNP concentration_NN as_IN described_VBN
          previously_RB [_NN 23_CD ]_NN ._. Conditions_NNP for_IN optimal_NN gene_NN
          expression_NN were_VBD established_VBN by_IN testing_VBG luciferase_NN
          activity_NN in_IN the_DT skin_NN 48_CD h_NN following_VBG injection_NN of_IN
          pHCMVIE_NN 1_CD -_: luciferase_NN ._. The_DT set_NN of_IN conditions_NNS (_( pressure_NN /_NN PVP_NNP
          concentration_NN /_NN gold_NN and_CC DNA_NNP amounts_NNS )_) with_IN the_DT highest_JJS mean_NN
          luciferase_NN expression_NN and_CC optimal_NN skin_NN penetration_NN was_VBD
          chosen_VBN as_IN the_DT optimal_NN combination_NN for_IN immunization_NN
          studies_NNS ._. This_DT optimal_NN setting_VBG of_IN one_CD μg_NN plasmid_NN DNA_NNP
          prepared_VBD with_IN 0_CD ._. 05_CD mg_NN /_NN ml_NN PVP_NNP /_NN 0_CD ._. 50_CD mg_NN gold_NN delivered_VBN at_IN
          360_CD psi_NN was_VBD utilized_JJ for_IN each_DT immunization_NN time_NN
          point_NN ._.
          A_DT plasmid_NN DNA_NNP solution_NN at_IN 1_CD μg_NN /_NN μl_NN was_VBD prepared_VBN in_IN PBS_NNP ._.
          A_DT 29_CD -_: gauge_VB needle_NN and_CC 1_CD ml_NN syringe_NN were_VBD utilized_JJ for_IN
          intra-dermal_JJ injection_NN ._. Conditions_NNP for_IN optimal_NN gene_NN
          expression_NN in_IN the_DT injected_VBN skin_NN were_VBD established_VBN prior_RB to_TO
          the_DT genetic_JJ immunization_NN experiments_NNS ._. When_WRB using_VBG needle_NN
          and_CC syringe_NN injection_NN for_IN intradermal_NN delivery_NN the_DT goal_NN
          is_VBZ contain_VB the_DT delivery_NN solution_NN within_IN the_DT epidermis_NNS and_CC
          dermis_NNS but_CC optimize_NN gene_NN expression_NN levels_NNS ._. Conditions_NNP
          for_IN optimal_NN gene_NN expression_NN were_VBD established_VBN by_IN testing_VBG
          luciferase_NN activity_NN in_IN the_DT skin_NN 48_CD h_NN following_VBG injection_NN
          of_IN pHCMVIE_NN 1_CD -_: luciferase_NN ._. A_DT maximum_NN of_IN 20_CD μl_NN /_NN 20_CD μg_NN plasmid_NN
          DNA_NNP could_MD be_VB injected_VBN and_CC kept_VBN contained_VBN within_IN the_DT
          epidermis_NNS and_CC dermis_NNS ._. This_DT volume_NN yielded_VBD the_DT highest_JJS
          luciferase_NN values_NNS ._. The_DT optimal_NN condition_NN of_IN twenty_CD μl_NN (_( 20_CD
          μg_NN plasmid_NN DNA_NNP )_) was_VBD delivered_VBN at_IN each_DT immunization_NN time_NN
          point_NN ._.
        
        
          Luciferase_NNP Assay_NNP
          Two_CD days_NNS after_IN injection_NN rabbits_NNS were_VBD euthanized_JJ and_CC
          the_DT area_NN of_IN injected_VBN skin_NN excised_VBD ._. Skin_NNP tissue_NN was_VBD
          homogenized_JJ in_IN lysis_NNS reagent_NN buffer_NN (_( Luciferase_NNP Assay_NNP
          System_NNP ,_, Promega_NNP ,_, Madison_NNP ,_, WI_NNP )_) ._. For_IN each_DT injection_NN sample_NN ,_,
          luciferase_NN activity_NN was_VBD measured_VBN in_IN duplicate_VB using_VBG a_DT
          TD-_NNP 20_CD /_NN 20_CD Luminometer_NNP (_( Turner_NNP Designs_NNS ,_, Sunnyvale_NNP ,_, CA_NNP )_) [_NN 2_CD
          ]_NN ._.
        
        
          Enzyme-linked_NNP immunosorbent_NN assay_NN (_( ELISA_NNP )_)
          Affinity-purified_NNP recombinant_JJ Hepatitis_NNP B_NNP antigen_NN
          produced_VBN in_IN Saccharomyces_NNP cerevisae_NN following_VBG
          transformation_NN with_IN the_DT plasmid_NN pCGA_NN 7_CD was_VBD used_VBN for_IN
          detection_NN of_IN antibody_NN responses_NNS using_VBG an_DT ELISA_NNP (_( Aldevron_NNP ,_,
          Fargo_NNP ,_, ND_NNP )_) [_NN 20_CD ]_NN ._. The_DT recombinant_JJ antigens_NNS were_VBD diluted_VBN
          in_IN 0_CD ._. 1_CD M_NNP carbonate_NN buffer_NN (_( pH_NN 9_CD ._. 6_CD )_) and_CC coated_JJ at_IN 1_CD ug_NN /_NN 100_CD
          ul_NN per_IN well_RB in_IN 96_CD -_: well_RB microtitre_NN plates_NNS (_( Dynex_NNP
          Technologies_NNPS ,_, INC_NNP ._. Chantilly_NNP ,_, VA_NNP )_) ._. Adjoining_NNP negative_JJ
          control_NN wells_NNS were_VBD coated_VBN with_IN 0_CD ._. 1_CD M_NNP carbonate_NN buffer_NN (_( pH_NN
          9_CD ._. 6_CD )_) alone_RB ._. The_DT plates_NNS were_VBD incubated_JJ at_IN 4_CD °_NN C_NNP overnight_JJ ._.
          Plates_NNP were_VBD washed_VBN three_CD times_NNS in_IN phosphate_NN buffered_JJ
          saline_NN (_( PBS_NNP )_) (_( pH_NN 7_CD ._. 4_LS )_) and_CC blocked_VBN with_IN 5_CD %_NN bovine_JJ serum_NN
          albumin_NN (_( BSA_NNP )_) in_IN PBS_NNP before_IN serum_NN was_VBD added_VBN ._. One_CD hundred_CD
          ul_NN of_IN PBS-Tween-_NNP 20_CD with_IN 1_CD %_NN BSA_NNP was_VBD added_VBN to_TO each_DT well_RB ._. To_TO
          quantify_VB the_DT antibody_NN response_NN at_IN the_DT different_JJ time_NN
          points_NNS after_IN injection_NN (_( s_VBZ )_) for_IN each_DT rabbit_NN ,_, 100_CD ul_NN of_IN
          diluted_VBN serum_NN samples_NNS at_IN 1_CD :_: 25_CD ,_, 1_CD :_: 250_CD and_CC 1_CD :_: 2_CD ,_, 500_CD were_VBD
          added_VBN to_TO separate_JJ wells_NNS in_IN duplicate_VB ._. Assays_NNP for_IN all_DT time_NN
          points_NNS were_VBD performed_VBN simultaneously_RB ._. The_DT entire_JJ assay_NN
          was_VBD repeated_VBN at_IN least_JJS twice_RB for_IN all_DT samples_NNS ._. Rabbit_NNP sera_NN
          obtained_VBN prior_RB to_TO any_DT injection_NN were_VBD utilized_JJ as_IN negative_JJ
          controls_NNS ._. The_DT plate_NN was_VBD incubated_JJ at_IN 37_CD °_NN C_NNP for_IN 1_CD h_NN ._. After_IN
          additional_JJ washing_NN ,_, phosphatase-conjugated_JJ goat_NN
          anti-rabbit_JJ IgG_NNP antibody_NN was_VBD added_VBN into_IN each_DT sample_NN well_RB
          and_CC incubated_JJ for_IN 1_CD h_NN at_IN 37_CD °_NN C_NNP ._. Diethanolamine_NNP (_( DEA_NNP )_)
          buffer_NN phosphatase_NN substrate_NN (_( Kirkegaard_NNP Perry_NNP Lab_NNP ,_,
          Gaithersburg_NNP ,_, Maryland_NNP )_) was_VBD added_VBN into_IN all_DT wells_NNS and_CC the_DT
          plates_NNS were_VBD incubated_JJ for_IN 30_CD min_NN at_IN room_NN temperature_NN in_IN
          the_DT dark_NN ._. The_DT reaction_NN was_VBD terminated_VBN after_IN the_DT
          appearance_NN of_IN color_NN using_VBG 3_CD N_NNP NaOH_NNP ._. The_DT absorbance_NN was_VBD
          measured_VBN at_IN 410_CD nm_NN using_VBG a_DT microplate_NN reader_NN (_( Emax_NNP ,_,
          Sunnyvale_NNP ,_, CA_NNP )_) ._. The_DT mean_JJ value_NN for_IN each_DT set_NN of_IN duplicate_VB
          wells_NNS was_VBD determined_VBN ._. Specific_JJ binding_VBG to_TO the_DT Hepatitis_NNP B_NNP
          antigen_NN was_VBD determined_VBN by_IN subtracting_VBG the_DT mean_JJ value_NN from_IN
          the_DT negative_JJ control_NN wells_NNS that_WDT were_VBD coated_VBN with_IN buffer_NN
          alone_RB from_IN the_DT mean_JJ value_NN from_IN the_DT Hepatitis_NNP B-_NNP coated_JJ
          experimental_JJ wells_NNS ._. Rabbits_NNP defined_VBD as_IN demonstrating_VBG an_DT
          immune_JJ response_NN exhibited_VBN a_DT statistically_RB significantly_RB
          higher_JJR mean_NN absorbance_NN reading_NN following_VBG injection_NN
          measured_VBN at_IN serum_NN dilutions_NNS of_IN 1_CD :_: 250_CD and_CC 1_CD :_: 2_CD ,_, 500_CD at_IN a_DT
          minimum_NN of_IN two_CD serial_NN time_NN points_NNS following_VBG injection_NN as_IN
          compared_VBN to_TO mean_VB values_NNS for_IN negative_JJ control_NN serum_NN ._.
        
        
          Statistical_NNP analysis_NN
          Means_NNP and_CC standard_JJ errors_NNS (_( S_NNP ._. E_NNP ._. )_) for_IN the_DT luciferase_NN
          expression_NN assays_NNS and_CC antibody_NN responses_NNS as_IN measured_VBN by_IN
          ELISA_NNP were_VBD calculated_VBN (_( SPSS_NNP 9_CD ._. 0_CD ,_, SPSS_NNP ,_, Inc_NNP ._. ,_, Chicago_NNP ,_,
          IL_NNP )_) ._. Mean_VB antibody_NN responses_NNS were_VBD compared_VBN by_IN ANOVA_NNP (_( SPSS_NNP
          9_CD ._. 0_CD )_) ._. 
          P_NN ≤_NN 0_CD ._. 05_CD was_VBD considered_VBN a_DT
          statistically_RB significant_JJ difference_NN ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        S_NNP ._. R_NN ._. performed_VBD the_DT low-volume_JJ jet_NN and_CC needle_NN and_CC syringe_NN
        injections_NNS ,_, collected_VBN tissues_NNS ,_, analyzed_VBD luciferase_NN
        expression_NN levels_NNS ,_, prepared_VBD the_DT serum_NN for_IN analysis_NN ,_,
        developed_VBN and_CC performed_VBD the_DT ELISA_NNP ._. M_NNP ._. L_NNP ._. assisted_VBN with_IN the_DT
        low-volume_JJ jet_NN and_CC needle_NN and_CC syringe_NN injections_NNS and_CC
        development_NN of_IN the_DT ELISA_NNP ._. J_NNP ._. M_NNP ._. S_NNP ._. prepared_VBD the_DT gold_JJ
        particles_NNS for_IN injection_NN ,_, performed_VBD the_DT particle_NN bombardment_NN
        injections_NNS ,_, anesthetized_JJ the_DT rabbits_NNS and_CC prepared_VBD the_DT skin_NN
        for_IN injection_NN ,_, collected_VBD the_DT blood_NN from_IN the_DT rabbits_NNS ,_, wrote_VBD
        the_DT materials_NNS and_CC methods_NNS section_NN on_IN particle_NN bombardment_NN ,_,
        and_CC edited_JJ the_DT manuscript_NN ._. L_NNP ._. J_NNP ._. D_NNP ._. assisted_VBN with_IN the_DT
        development_NN of_IN the_DT animal_NN protocols_NNS and_CC particle_NN
        bombardment_NN procedure_NN and_CC edited_JJ the_DT manuscript_NN ._. P_NN ._. A_DT ._. F_NN ._.
        designed_VBD the_DT experiments_NNS ,_, supervised_VBD the_DT performance_NN of_IN the_DT
        low-volume_JJ jet_NN and_CC needle_NN and_CC syringe_NN injections_NNS ,_,
        luciferase_NN assays_NNS and_CC the_DT ELISA_NNP ,_, performed_VBD the_DT statistical_JJ
        analyses_NNS ,_, prepared_VBD the_DT figures_NNS ,_, and_CC wrote_VBD the_DT manuscript_NN
        for_IN publication_NN ._. All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ
        manuscript_NN ._.
      
    
  
